Why is the Milky Way X-factor constant? [PDF]
, 2013 The CO-H2 conversion factor (Xco; otherwise known as the X-factor) is observed to be remarkably constant in the Milky Way and in the Local Group (aside from the SMC). To date, our understanding of why Xco should be so constant remains poor.
Desika Narayanan, Philip F. Hopkins
openalex +5 more sources
Factor X and combined factor VIIa/factor X augment coagulation potential in a plasma model of antithrombin-reduced hemophilia [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Plasma-derived (pd) factor (F)VIIa/FX products are available for the hemostatic management of people with hemophilia with inhibitors in Japan. We have previously reported that FX alone augments emicizumab-driven hemostasis.
Shigeharu Oh +4 more
doaj +2 more sources
Anesthesia strategy for factor X deficiency coagulopathy: case report [PDF]
Brazilian Journal of Anesthesiology, 2022 Factor X deficiency ranks among the rarest coagulopathies and has a variable presentation spectrum. We intend to present a proposal for anesthesia protocol for individuals with the coagulopathy.
Carla Isabel Ferreira +5 more
doaj +2 more sources
Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X [PDF]
Blood Advances: Formation of the extrinsic complex (EC) on cell surfaces is the event that triggers the coagulation cascade. Tissue factor (TF) and factor VIIa (FVIIa) form the EC together with FX on phosphatidylserine-containing membranes, leading to FX activation by
Melanie P. Muller +5 more
doaj +2 more sources
Combined Factor VII and X Deficiency [PDF]
Online Journal of Health & Allied Sciences, 2011 Factor VII deficiency and factor X deficiency and very rare disorders individually. Combined Factor VII and X is a rare congenital blood disorder with very few cases reported in the literature.
Gursharan Singh Narang, +2 more
doaj +1 more source
Plasma‐derived factor X concentrate compassionate use for hereditary factor X deficiency: Long‐term safety and efficacy in a retrospective data‐collection study [PDF]
Research and Practice in Thrombosis and Haemostasis, 2021 Background Coagadex is a high‐purity plasma‐derived factor X concentrate (pdFX) developed to treat hereditary factor X deficiency (FXD). Objective Evaluate the efficacy and safety of pdFX administered to patients with hereditary FXD.
James N. Huang +4 more
doaj +2 more sources
Circulating Inhibitor against Factor X: A Rare Cause of Hemorrhagic Diathesis [PDF]
Case Reports in Hematology, 2023 Acquired coagulopathies resulting from factor X deficiency are rare and typically associated with amyloidosis or plasma cell dyscrasia. Factor X plays a pivotal role in the coagulation cascade, converting prothrombin into thrombin and facilitating the ...
P. Rossignon +3 more
doaj +2 more sources
Factor X Concentrate Treatment Schedule and Dosing in Acquired FX Deficiency [PDF]
Hematology ReportsBackground: Acquired factor X (FX) deficiency is a rare condition that can cause life threatening bleeding. Here we outline a successful management strategy for gastrointestinal bleeding (GI) using human FX concentrate.
Andrew Ross +3 more
doaj +2 more sources
A rare case of factor X deficiency induced by valproic acid [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Factor X (FX) deficiency (FXD) significantly disrupts coagulation, potentially leading to severe bleeding. While inherited FXD is rare, with a prevalence of 1 in 500,000, acquired FXD is also uncommon and frequently linked to conditions such ...
Pierre-Antonin Rigon, Vincent Ernest
doaj +2 more sources
A new look at TFPI inhibition of factor X activation. [PDF]
PLoS Computational BiologyBlood coagulation is a vital physiological process involving a complex network of biochemical reactions, which converge to form a blood clot that repairs vascular injury.
Fabian Santiago +5 more
doaj +2 more sources